CMV and transfusions, an old story that's not quite over yet

References

• Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol. 2008;197(2):65–73.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121(5):1673–1680.
   PubMed Web of Science ®Google Scholar
• Kantor GL, Goldberg LS, Johnson BL Jr, Derechin, MM, Barnett EV. Immunologic abnormalities induced by postperfusion cytomegalovirus infection. Ann Intern Med. 1970;73(4):553–558.
   Web of Science ®Google Scholar
• Stevens DP, Barker LF, Ketcham AS, Meyer HM Jr. Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery. JAMA. 1970;211(8):1341–1344.
   Web of Science ®Google Scholar
• Lerner PI, Sampliner JE. Transfusion-associated cytomegalovirus mononucleosis. Ann Surg. 1977;185(4):406–410.
   Web of Science ®Google Scholar
• Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22(1):76–98.
   PubMed Web of Science ®Google Scholar
• Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ. 1973;49(1):103–106.
   PubMed Web of Science ®Google Scholar
• Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis. 2010;50(11):1439–1447.
   PubMed Web of Science ®Google Scholar
• Collier AC, Meyers JD, Corey L, Murphy VL, Roberts PL, Handsfield HH. Cytomegalovirus infection in homosexual men. Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. Am J Med. 1987;82(3 Spec No):593–601.
   Web of Science ®Google Scholar
• Roitt I, Brostoff J, Male D. Immunology. 6th ed. St Louis: Mosby; 2001.
   Google Scholar
• Compton T, Kurt-Jones EA, Boehme EW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003;77(8):4588–4596.
   PubMed Web of Science ®Google Scholar
• Venema H, van den Berg AP, van Zanten C, van Son WJ, van der Giessen M, The TH. Natural killer cell responses in renal transplant patients with cytomegalovirus infection. J Med Virol. 1994;42(2):188–192.
   Web of Science ®Google Scholar
• Hadaya K, de Rham C, Bandelier C, et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV Infection after kidney transplantation. Am J Transplant. 2008;8(12):2674–2683.
   Web of Science ®Google Scholar
• Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect. 2002;4(15):1545–1558.
   PubMed Web of Science ®Google Scholar
• Jonjić S, Pavić I, Polić B, Crnković I, Lucin P, Koszinowski UH. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med. 1994;179(5):1713–1717.
   Web of Science ®Google Scholar
• Klenovsek K, Weisel F, Schneider A, et al. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood. 2007;110(9):3472–3479.
   PubMed Web of Science ®Google Scholar
• Sester M, Gärtner BC, Sester U, Girndt M, Mueller-Lantzsch N, Köhler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation. 2003;76(8):1229–1230.
   Web of Science ®Google Scholar
• Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients. N Engl J Med. 1987;317(17):1049–1054.
   PubMed Web of Science ®Google Scholar
• Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353(13):1350–1362.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation [review]. Cochrane Database Syst Rev. 2008;4:CD006501.
   Google Scholar
• Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78(5):1373–1380.
   PubMed Web of Science ®Google Scholar
• Widmann T, Sester U, Gärtner BC, et al. Levels of CMV Specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One. 2008;3(11):e3634.
   PubMed Web of Science ®Google Scholar
• Sester U, Gärtner BC, Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant. 2005;5(6):1483–1489.
   PubMed Web of Science ®Google Scholar
• Déchanet J, Merville P, Bergé F, et al. Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J Infect Dis. 1999;179(1):1–8.
   Web of Science ®Google Scholar
• Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–241.
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038–1044.
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916–3922.
   PubMed Web of Science ®Google Scholar
• Sester M, Sester U, Gärtner BC, Girndt M, Meyerhans A, Köhler H. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol. 2002;13(10):2577–2584.
   PubMed Web of Science ®Google Scholar
• Elkington R, Shoukry NH, Walker S, et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol. 2004;34(11):3216–3226.
   Web of Science ®Google Scholar
• Klenerman P, Dunbar PR. CMV and the art of memory maintenance. Immunity. 2008;29(4):520–522.
   Web of Science ®Google Scholar
• Goodrum F, Caviness K, Zagallo P. Human cytomegalovirus persistence. Cell Microbiol. 2012;14(5):644–655.
   PubMed Web of Science ®Google Scholar
• Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res. 2011;157(2):151–160.
   PubMed Web of Science ®Google Scholar
• Mocarski ES Jr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 2002;10(7):332–339.
   PubMed Web of Science ®Google Scholar
• Cook CH, Trgovcich J. Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges. Antiviral Res. 2011;90(3):151–159.
   Web of Science ®Google Scholar
• Kurz S, Steffens HP, Mayer A, Harris JR, Reddehase MJ. Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol. 1997;71(4):2980–2987.
   Web of Science ®Google Scholar
• Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect. 2007;13(10):953–963.
   Web of Science ®Google Scholar
• Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF. Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog. 2011;7(5):e1001344.
   Web of Science ®Google Scholar
• Miller DM, Zhang Y, Rahill BM, Waldman WJ, Sedmak DD. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal Transduction. J Immunol. 1999;162(10):6107–6113.
   Web of Science ®Google Scholar
• Terhune S, Torigoi E, Moorman N, Silva M, Qian Z, Shenk T, Yu D. Human cytomegalovirus UL38 protein blocks apoptosis. J Virol. 2007;81(7):3109–3123.
   Web of Science ®Google Scholar
• Marshall EE, Geballe AP. Multifaceted evasion of the interferon response by cytomegalovirus. J Interferon Cytokine Res. 2009;29(9):609–619.
   Web of Science ®Google Scholar
• Slobedman B, Barry PA, Spencer JV, Avdic S, Abendroth A. Virus-encoded homologs of cellular interleukin-10 and their control of host immune function. J Virol. 2009;83(19):9618–9629.
   PubMed Web of Science ®Google Scholar
• Wilkinson GW, Tomasec P, Stanton RJ, et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol. 2008;41(3):206–212.
   PubMed Web of Science ®Google Scholar
• Hegde NR, Tomazin RA, Wisner TW, et al. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol. 2002;76(21):10929–10941.
   PubMed Web of Science ®Google Scholar
• Luck S, Sharland M. Postnatal cytomegalovirus: innocent bystander or hidden problem? Arch Dis Child Fetal Neonatal Ed. 2009;94(1):F58–F64.
   Web of Science ®Google Scholar
• Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA. 1986;256(14):1904–1908.
   PubMed Web of Science ®Google Scholar
• Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001;344(18):1366–1371.
   PubMed Web of Science ®Google Scholar
• Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253–276.
   PubMed Web of Science ®Google Scholar
• Advisory Committee on the Safety of Blood, Tissues and Organs. Report of the Cytomegalovirus Steering Group. London: Advisory Committee on the Safety of Blood, Tissues and Organs; 2012. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215126/dh_132966.pdf. Accessed November 28, 2013.
   Google Scholar
• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4(12):725–738.
   PubMed Web of Science ®Google Scholar
• Sissons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus infection. J Infect. 2002;44(2):78–83.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–5719.
   PubMed Web of Science ®Google Scholar
• Hassan-Walker AF, Kidd IM, Sabin C, Sweny P, Griffiths PD, Emery VC. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol. 1999;58(2):182–187.
   Web of Science ®Google Scholar
• Sandherr M, Einsele H, Hebart H, et al; Infectious Diseases Working Party, German Society for Hematology and Oncology. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol. 2006;17(7):1051–1059.
   Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–360.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094–1097.
   PubMed Web of Science ®Google Scholar
• Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 2008;46(6):840–846.
   PubMed Web of Science ®Google Scholar
• Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation. 2010;90(6):672–676.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Atlanta, GA, USA: Centers for Disease Control and Prevention; 2009. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm Accessed November dd, 2013.
   Google Scholar
• Freeman RB Jr. The ‘indirect’ effects of cytomegalovirus infection. Am J Transplant. 2009;9(11):2453–2458.
   PubMed Web of Science ®Google Scholar
• Varani S, Landini MP. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae. 2011;2(1):6.
   PubMedGoogle Scholar
• Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998;26(3):753–755.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273–282.
   PubMed Web of Science ®Google Scholar
• Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002;8(4):362–369.
   Web of Science ®Google Scholar
• Fernández EJ, Auyanet I, Guerra R, et al. [Primary cytomegalovirus infection causing a kidney transplant patient to develop cryoagglutinins and cryoglobulins]. Nefrologia. 2010;30(2):267–268. Spanish.
   Web of Science ®Google Scholar
• Mengarelli A, Minotti C, Palumbo G, et al. High levels of antiphospholipid antibodies are associated with cytomegalovirus infection in unrelated bone marrow and cord blood allogeneic stem cell transplantation. Br J Haematol. 2000;108(1):126–131.
   Web of Science ®Google Scholar
• Sekigawa I, Nawata M, Seta N, Yamada M, Iida N, Hashimoto H. Cytomegalovirus infection in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2002;20(4):559–564.
   Web of Science ®Google Scholar
• Lidar M, Lipschitz N, Langevitz P, et al. Infectious serologies and autoantibodies in Wegener’s granulomatosis and other vasculitides: novel associations disclosed using the Rad BioPlex 2200. Ann N Y Acad Sci. 2009;1173:649–657.
   PubMed Web of Science ®Google Scholar
• Valderhaug TG, Hjelmesaeth J, Rollag H, et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation. 2007;84(9):1125–1130.
   Web of Science ®Google Scholar
• Potena L, Valantine HA. Cytomegalovirus and development of cardiac allograft vasculopathy: evidences and therapeutic implications. Trends in Transplant. 2010;4:108–116.
   Google Scholar
• Simmonds J, Fenton M, Dewar C, et al. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation. 2008;117(20):2657–2661.
   Web of Science ®Google Scholar
• Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004;66(1):329–337.
   PubMed Web of Science ®Google Scholar
• Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant. 2009;28(5):461–467.
   PubMed Web of Science ®Google Scholar
• Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300(4):413–422.
   PubMed Web of Science ®Google Scholar
• Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infections. Infect Disord Drug Targets. 2011;11(5):466–474.
   PubMedGoogle Scholar
• Schmidt T, Ritter M, Dirks J, Gärtner BC, Sester U, Sester M. Cytomegalovirus-specific T-cell immunity to assign the infection status in individuals with passive immunity: a proof of principle. J Clin Virol. 2012;54(3):272–275.
   Web of Science ®Google Scholar
• cdc.gov [homepage on the Internet]. Cytomegalovirus (CMV) and congenital CMV infection. Centers for Disease Control and Prevention; 2010 [updated December 6, 2010]. Available from: http://www.cdc.gov/cmv/clinical/lab-tests.html. Accessed November 28, 2013.
   Google Scholar
• Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant. 2006;6(10):2356–2364.
   Web of Science ®Google Scholar
• British Transplantation Society. Guidelines for the Prevention and Management of CMV Disease after Solid Organ Transplantation. Cheshire, UK: British Transplantation Society; 2011. Available from: http://www.bts.org.uk/Documents/Guidelines/Active/Final%20CMV%20Guideline%20for%20web%2012-9-2011.pdf. Accessed November 28, 2013.
   Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009;27(5):770–781.
   PubMed Web of Science ®Google Scholar
• Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006;82(3):398–405.
   PubMed Web of Science ®Google Scholar
• Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011;1(6):548–554.
   Web of Science ®Google Scholar
• Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314(16):1006–1010.
   PubMed Web of Science ®Google Scholar
• Miller WJ, McCullough J, Balfour HH Jr, Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 1991;7(3):227–234.
   Web of Science ®Google Scholar
• Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion. 2007;47(11):1972–1983.
   Web of Science ®Google Scholar
• Booth JC, Hannington G, Bakir TM, et al. Comparison of enzyme-linked immunosorbent assay, radioimmunoassay, complement fixation, anticomplement immunofluorescence and passive haemagglutination techniques for detecting cytomegalovirus IgG antibody. J Clin Pathol. 1982;35(12):1345–1348.
   Web of Science ®Google Scholar
• Taswell HF, Reisner RK, Rabe DE, Shelley CD, Smith TF. Comparison of three methods for detecting antibody to cytomegalovirus. Transfusion. 1986;26(3):285–289.
   Web of Science ®Google Scholar
• Logan S, Barbara J, Kovar I. Cytomegalovirus screened blood for neonatal intensive care units. Arch Dis Child. 1988;63(7 Spec No):753–755.
   Web of Science ®Google Scholar
• Faix RG. Cytomegalovirus antigenic heterogeneity can cause false-negative results in indirect hemagglutination and complement fixation antibody assays. J Clin Microbiol. 1985;22(5):768–771.
   Web of Science ®Google Scholar
• Larsson S, Söderberg-Nauclér C, Wang FZ, Möller E. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion. 1998;38(3):271–278.
   Web of Science ®Google Scholar
• Roback JD, Drew WL, Laycock ME, Todd D, Hillyer CD, Busch MP. CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion. 2003;43(3):314–321.
   Web of Science ®Google Scholar
• Drew WL, Roback JD. Prevention of transfusion-transmitted cytomegalovirus: reactivation of the debate? Transfusion. 2007;47(11):1955–1958.
   Web of Science ®Google Scholar
• Patterson BJ, Freedman J, Blanchette V, et al. Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions. Transfus Med. 2000;10(3):199–206.
   Web of Science ®Google Scholar
• Pruss A, Kalus U, Radtke H, et al. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Transfus Apher Sci. 2004;30(1):41–46.
   PubMed Web of Science ®Google Scholar
• Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol. 1981;9(1):77–83.
   Web of Science ®Google Scholar
• Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood. 1983;62(4):815–820.
   Web of Science ®Google Scholar
• McFarland J, Menitove J, Kagen L, et al. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med. 1997;337(26):1861–1869.
   Web of Science ®Google Scholar
• Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004;103(1):333–339.
   Web of Science ®Google Scholar
• Bilgin YM, Brand A. Transfusion-related immunomodulation: a second hit in an inflammatory cascade? Vox Sang. 2008;95(4):261–271.
   Web of Science ®Google Scholar
• Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev. 2010;24(2):77–124.
   PubMed Web of Science ®Google Scholar
• Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion. 2007;47(8):1455–1467.
   Web of Science ®Google Scholar
• Sparrow RL, Patton KA. Supernatant from stored red blood cell primes inflammatory cells: influence of prestorage white cell reduction. Transfusion. 2004;44(5):722–730.
   PubMed Web of Science ®Google Scholar
• Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105(6):2266–2273.
   PubMed Web of Science ®Google Scholar
• Cervia JS, Wenz B, Ortolano GA. Leukocyte reduction’s role in the attenuation of infection risks among transfusion recipients. Clin Infect Dis. 2007;45(8):1008–1013.
   PubMed Web of Science ®Google Scholar
• Gregori L, McCombie N, Palmer D, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet. 2004;364(9433):529–531.
   Web of Science ®Google Scholar
• Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol. 2006;132(1):13–24.
   PubMed Web of Science ®Google Scholar
• Davidson F, Lycett C, Jarvis LM, et al. Detection of HTLV-I and -II in Scottish blood donor samples and archive donations. Vox Sang. 2006;91(3):231–236.
   Web of Science ®Google Scholar
• Davison KL, Dow B, Barbara JA, Hewitt PE, Eglin R. The introduction of anti-HTLV testing of blood donations and the risk of transfusion-transmitted HTLV, UK: 2002–2006. Transfus Med. 2009; 19(1):24–34.
   Web of Science ®Google Scholar
• Rawal BD, Busch MP, Endow R, et al. Reduction of human immunodeficiency virus-infected cells from donor blood by leukocyte filtration. Transfusion. 1989;29(5):460–462.
   Web of Science ®Google Scholar
• Bruisten SM, Tersmette M, Wester MR, Vos AHV, Koppelman MH, Huisman JG. Efficiency of white cell filtration and a freeze-thaw procedure for removal of HIV-infected cells from blood. Transfusion. 1990;30(9):833–837.
   Web of Science ®Google Scholar
• Vamvakas EC. The case against universal white blood cell reduction. ISBT Science Series. 2006;1(1):64–72.
   Google Scholar
• Brady MT, Milam JD, Anderson DC, et al. Use of deglycerolized red blood cells to prevent posttransfusion infection with cytomegalovirus in neonates. J Infect Dis. 1984;150(3):334–339.
   Web of Science ®Google Scholar
• Luban NL, Williams AE, MacDonald MG, Mikesell GT, Williams KM, Sacher RA. Low incidence of acquired cytomegalovirus infection in neonates transfused with washed red blood cells. Am J Dis Child. 1987;141(4):416–419.
   Google Scholar
• Gilbert GL, Hayes K, Hudson IL, James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet. 1989;1(8649):1228–1231.
   PubMed Web of Science ®Google Scholar
• Eisenfeld L, Silver H, McLaughlin J, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion. 1992;32(3):205–209.
   Web of Science ®Google Scholar
• Triulzi DJ, Dzik WH. Leukocyte-reduced blood components: laboratory and clinical aspects. In: Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG, Petrides M, editors. Rossi’s Principles of Transfusion Medicine. Chichester, UK: Wiley-Blackwell; 2009: 228–246.
   Google Scholar
• Kakaiya R, Aronson CA, Julleis J. Whole blood collection and component processing. In: Roback JD, Combs MR, Grossman BJ, Hillyer CD, editors. Technical Manual, 16th edition. Bethesda, MD: AABB; 2008:189–228.
   Google Scholar
• Dumont LJ, Luka J, VandenBroeke T, Whitley P, Ambruso DR, Elfath MD. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood. 2001;97(11):3640–3647.
   Web of Science ®Google Scholar
• Verdonck LF, de Graan-Hentzen YC, Dekker AW, Mudde GC, de Gast GC. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant. 1987;2(1):73–78.
   Web of Science ®Google Scholar
• Murphy MF, Grint PCA, Hardiman AE, Lister TA, Waters AH. Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia. Br J Haematol. 1988;70(2):253–254.
   Web of Science ®Google Scholar
• de Graan-Hentzen YC, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion. 1989;29(9):757–760.
   Web of Science ®Google Scholar
• van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol. 1994;87(1):144–147.
   Web of Science ®Google Scholar
• Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 1991;78(1):246–250.
   PubMed Web of Science ®Google Scholar
• Pamphilon DH, Foot ABM, Adeodu A, et al. Prophylaxis and prevention of CMV infection in BM allograft recipients: Leucodepleted platelets are equivalent to those from CMV seronegative donors. Bone Marrow Transplant. 1999;23(Suppl 1):S66.
   Google Scholar
• Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101(10):4195–4200.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Larsson K, Kumlien G, et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis. 2002;34(5):347–350.
   PubMed Web of Science ®Google Scholar
• Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV Infection after marrow transplant. Blood. 1995;86(9):3598–3603.
   PubMed Web of Science ®Google Scholar
• James DJ, Sikotra S, Sivakumaran M, et al. The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transfus Med. 1997;7(2):123–126.
   Web of Science ®Google Scholar
• Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005;19(3):181–199.
   Web of Science ®Google Scholar
• Ziemann M, Heuft HG, Frank K, Kraas S, Görg S, Hennig H. Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion. 2013;53(5):1088–1094.
   Web of Science ®Google Scholar
• Furui Y, Satake M, Hoshi Y, Uchida S, Suzuki K, Tadokoro K. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion. 2013;53(10):2190–2197.
   PubMed Web of Science ®Google Scholar
• Dollard SC, Roback JD, Gunthel C, et al. Measurements of human herpesvirus 8 viral load in blood before and after leukoreduction filtration. Transfusion. 2013;53(10):2164–2167.
   Web of Science ®Google Scholar
• Roback JD, Josephson CD. New insights for preventing transfusion-transmitted cytomegalovirus and other white blood cell-associated viral infections. Transfusion. 2013; 53(10):2112–2116.
   Web of Science ®Google Scholar
• Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med. 2007;131(5):719–733.
   PubMed Web of Science ®Google Scholar
• Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406–3417.
   PubMed Web of Science ®Google Scholar
• Marschner S, Goodrich R. Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light. Transfus Med Hemother. 2011;38(1):8–18.
   PubMed Web of Science ®Google Scholar
• Fast LD, DiLeone G, Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion. 2011;51(7):1397–1404.
   PubMed Web of Science ®Google Scholar
• van Rhenen D, Gulliksson H, Cazenave JP, et al; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101(6):2426–2433.
   PubMed Web of Science ®Google Scholar
• McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 2004;104(5):1534–1541.
   PubMed Web of Science ®Google Scholar
• Schleiss MR. Cytomegalovirus vaccine development. Curr Top Microbiol Immunol. 2008;325:361–382.
   PubMed Web of Science ®Google Scholar
• Sung S, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2010;9(11):1303–1314.
   PubMed Web of Science ®Google Scholar